In an in vivo study, administration of nintedanib alone could strongly suppress the stromal α-SMA-positive staining of xenograft tumours, but could not suppress the proportion of Ki-67-positive ICC cells strongly. This evidence concerns the gene ACTA1 and intrahepatic cholangiocarcinoma.